hepatocellular carcinoma
Conditions
Interventions
treatment group:combined cryoablation and thermal ablation
Sponsors
Renji Hospital, School of Medicine, Shanghai Jiaotong University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18-75 years; 2. Subjects with primary liver cancer confirmed by histology or cytology, with an expected survival period of >=12 weeks; 3. Confirmed by enhanced CT or MRI, single tumor, diameter =90g/L, platelet count (PLT)>=60x10^9/L; absolute neutrophil count>1.0x10^9/L; prothrombin activity (PTA)>50%; serum creatinine <1.5 times ULN; total bilirubin (TBIL) <51.3 umol/L (3 mg/dL); 7. The subjects voluntarily participated in the research, agreed to cooperate with the researcher in data collection, and signed the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Patients with tumor thrombus, extrahepatic metastasis, or liver transplantation in the large blood vessels of the liver; 2. Liver function classification is Child-Pugh C, which cannot be improved by liver protection treatment; 3. Uncorrectable coagulation dysfunction and obvious abnormal blood picture, with obvious bleeding tendency; 4. Intractable massive ascites; 5. Patients with severe heart, kidney, pulmonary dysfunction and severe mental disorders; 6. Previous or about to receive chemotherapy, molecular targeted therapy and/or immunotherapy such as PD1.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival; | — |
Countries
China
Contacts
Public ContactZhai Bo
Shanghai Jiaotong University School of Medicine, Renji Hospital
Outcome results
None listed